We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SEC ORDER AGAINST BMS COULD SIGNAL INCREASED ENFORCEMENT TREND
SEC ORDER AGAINST BMS COULD SIGNAL INCREASED ENFORCEMENT TREND
September 8, 2004
Stiff penalties contained in a Securities and Exchange Commission (SEC) order against Bristol-Myers Squibb (BMS) could be a harbinger of future crackdowns on drug manufacturers by the commission, as well as other federal agencies, according to drug industry observers.